



To hope and healing.

Partner Webinar

A yellow rectangular graphic with a repeating pattern of white question marks. In the center, there are two overlapping speech bubbles. The left bubble is black with the word "MYTH" in yellow. The right bubble is white with the word "TRUTH" in yellow. A small yellow circle with the word "vs" in black is positioned between the two bubbles.

MYTH vs TRUTH




December 17, 2020

The image features three glass vials with silver caps and a syringe on a reflective surface. The central vial is in sharp focus, with its label clearly visible. The label has a red border and contains the text 'COVID-19' in red and 'VACCINE' in black. The syringe is positioned to the right, lying horizontally. The background is a soft, out-of-focus grey.

Don't Hesitate,
Vaccinate!

Agenda

- **PSA: Suicide Prevention & Awareness**
 - **Dr. Karen Galin**
- **COVID-19 Vaccine Update**
 - **Dr. Bill Ruby**
- **Clinical Truths vs Myths**
 - **Dr. Ruby & Nancy Raines, RN**
- **What you can do to get ready**
 - **Karina Purcell, RN**





COVID-19: Suicide Prevention & Awareness

Dr. Karen Galin // Group Vice President, Mental Health

The image features three glass vials with silver caps and a syringe lying on a reflective surface. The central vial is in sharp focus, with its label clearly visible. The label has a red border and contains the text 'COVID-19' in red and 'VACCINE' in black. The syringe is positioned to the right, angled towards the bottom right corner. The background is a soft, out-of-focus blue-grey gradient.

COVID-19: Vaccination Update

Dr. Bill Ruby // Associate Chief Clinical Officer


Where Are We In Development?

PHASE 2 PHASE 3 COMBINED PHASES

Pfizer BIONTECH FOSUN PHARMA

Pfizer



- 95% effective
- **Dec 11, 2020 – received EUA**
- Deep Freeze storage
- 2 doses



moderna NIH National Institutes of Health
Turning Discovery Into Health


Moderna

- 94% effective
- **Nov. 30 NDA for EUA filed**
- **Expect Dec. 17, 2020 approval.**
- No Deep Freeze storage
- 2 doses



mRNA Vaccines:


Manufacturer	Requires Deep Freeze	Once Thawed how long before it MUST be administered?	Requires Diluent	How long after dilution must it be discarded?	Days till 2 nd Dose	Transported
Pfizer	Yes	Up to 5 days (undiluted and under refrigeration)	Yes	Discard 6 hours after dilution when stored at 2°C to 25°C (35° to 77° F)	21 days	Pfizer thermal shippers, dry ice for up to 10 days of storage
Moderna	No	12 hours at room temperature	No	N/A	28 days	-20°C (-4°F), equal to most home freezer



Dr. Bill Ruby // Associate Chief Clinical Officer



There is enough research completed on these vaccines.



Truth: There IS enough research completed on these new vaccines.

Table 3. Vaccine Efficacy Overall and by Subgroup in Participants without Evidence of Infection before 7 Days after Dose 2.

Efficacy End-Point Subgroup	BNT162b2 (N=18,198)		Placebo (N=18,325)		Vaccine Efficacy, % (95% CI) †
	No. of Cases	Surveillance Time (No. at Risk)*	No. of Cases	Surveillance Time (No. at Risk)*	
Overall	8	2.214 (17,411)	162	2.222 (17,511)	95.0 (90.0–97.9)
Age group					
16 to 55 yr	5	1.234 (9,897)	114	1.239 (9,955)	95.6 (89.4–98.6)
>55 yr	3	0.980 (7,500)	48	0.983 (7,543)	93.7 (80.6–98.8)
≥65 yr	1	0.508 (3,848)	19	0.511 (3,880)	94.7 (66.7–99.9)
≥75 yr	0	0.102 (774)	5	0.106 (785)	100.0 (–13.1–100.0)
Sex					
Male	3	1.124 (8,875)	81	1.108 (8762)	96.4 (88.9–99.3)
Female	5	1.090 (8,536)	81	1.114 (8,749)	93.7 (84.7–98.0)
Race or ethnic group ‡					
White	7	1.889 (14,504)	146	1.903 (14,670)	95.2 (89.8–98.1)
Black or African American	0	0.165 (1,502)	7	0.164 (1,486)	100.0 (31.2–100.0)
All others	1	0.160 (1,405)	9	0.155 (1,355)	89.3 (22.6–99.8)
Hispanic or Latinx	3	0.605 (4,764)	53	0.600 (4,746)	94.4 (82.7–98.9)
Non-Hispanic, non-Latinx	5	1.596 (12,548)	109	1.608 (12,661)	95.4 (88.9–98.5)
Country					
Argentina	1	0.351 (2,545)	35	0.346 (2,521)	97.2 (83.3–99.9)
Brazil	1	0.119 (1,129)	8	0.117 (1,121)	87.7 (8.1–99.7)
United States	6	1.732 (13,359)	119	1.747 (13,506)	94.9 (88.6–98.2)

2 Studies

Study 1: (PH I/II)
N=60

Study 2: (PH II/III)
N ~ 44,000

-16 or older

- Followed 2 months after 2nd dose

Study Participant Characteristics

- Includes patients at higher risk of severe COVID-19
- Hypertension, asthma (7.8%), DM (8.4%), HIV(120), HBV, HCV Obesity (35.1%)



The vaccines are proven effective.

Truth: The vaccines ARE proven effective.

Table 3. Vaccine Efficacy Overall and by Subgroup in Participants without Evidence of Infection before 7 Days after Dose 2.

Efficacy End-Point Subgroup	BNT162b2 (N=18,198)		Placebo (N=18,325)		Vaccine Efficacy, % (95% CI)†
	No. of Cases	Surveillance Time (No. at Risk)*	No. of Cases	Surveillance Time (No. at Risk)*	
Overall	8	2.214 (17,411)	162	2.222 (17,511)	95.0 (90.0–97.9)
Age group					
16 to 55 yr	5	1.234 (9,897)	114	1.239 (9,955)	95.6 (89.4–98.6)
>55 yr	3	0.980 (7,500)	48	0.983 (7,543)	93.7 (80.6–98.8)
≥65 yr	1	0.508 (3,848)	19	0.511 (3,880)	94.7 (66.7–99.9)
≥75 yr	0	0.102 (774)	5	0.106 (785)	100.0 (–13.1–100.0)
Sex					
Male	3	1.124 (8,875)	81	1.108 (8762)	96.4 (88.9–99.3)
Female	5	1.090 (8,536)	81	1.114 (8,749)	93.7 (84.7–98.0)
Race or ethnic group‡					
White	7	1.889 (14,504)	146	1.903 (14,670)	95.2 (89.8–98.1)
Black or African American	0	0.165 (1,502)	7	0.164 (1,486)	100.0 (31.2–100.0)
All others	1	0.160 (1,405)	9	0.155 (1,355)	89.3 (22.6–99.8)
Hispanic or Latinx	3	0.605 (4,764)	53	0.600 (4,746)	94.4 (82.7–98.9)
Non-Hispanic, non-Latinx	5	1.596 (12,548)	109	1.608 (12,661)	95.4 (88.9–98.5)
Country					
Argentina	1	0.351 (2,545)	35	0.346 (2,521)	97.2 (83.3–99.9)
Brazil	1	0.119 (1,129)	8	0.117 (1,121)	87.7 (8.1–99.7)
United States	6	1.732 (13,359)	119	1.747 (13,506)	94.9 (88.6–98.2)

Overall efficacy = 95%

Age ≥ 75 100%

Black or African American 100%





Clinical Trials

We know these
vaccines are safe.



Truth: These new vaccines are safe.

Study Population, N ~ 43,448


Adverse Reactions Coded as **SEVERE**

Adverse Reaction (mild, moderate, severe)	Percent (%)
Pain at injection site	84.1
Fatigue	62.9
Headache	55.1
Muscle Pain	38.3
Chills	31.9
Joint Pain	23.6
Fever	14.2
Injection Site Swelling	10.5
Injection Site Redness	9.5
Nausea	1.1
Malaise	0.5%
Lymphadenopathy	0.3

Adverse Reaction	Dose 1 (%)	Dose 2 (%)
Redness	0.3	0.5
Swelling	0.2	0.3
Pain	1.0	1.2
Fever <40°C (104)	0	0
Fatigue	1.4	4.6
Headache	1.0	3.2
Chills	0.4	2.1
Vomiting	0	0.2
Diarrhea	0.1	0.2
Muscle Pain	0.6	2.2
Joint Pain	0.2	1.0



6 Deaths

- 4 placebo
- 2 vaccine
 - > 55yo
 - Cardiac Arrest 62 days after 2nd dose
- Atherosclerosis 3 days after 1st dose



“I’m not getting the vaccine because I hear it uses a new genetic method and it is going to interact with my own DNA.”

Myth: The new mRNA vaccine process does NOT interact with the host's own DNA



The mRNA stays in the cell plasma and does not incorporate itself into the nucleus. Thus, no genetic material is coded into the host's genome.




**“The vaccine will
cause me to get
the COVID-19
disease.”**

Myth: Receiving the COVID-19 vaccine **WILL NOT** cause you to become infected.



- None of the COVID-19 vaccines currently in development in the United States use the live SARS CoV-2 virus.
- Vaccines currently in clinical trials in the U.S. will not cause you to test positive on viral tests, which are used to see if you have a current infection.

A woman with long brown hair is lying in a hospital bed, wearing a white hospital gown. She is holding a white tissue to her nose, appearing to be sneezing or blowing her nose. The background is a plain, light-colored wall. The image is overlaid with a dark grey semi-transparent box on the left side, containing white text.

**“I already had
COVID-19;
therefore, I don’t
need to get the
vaccine.”**

Myth: All eligible people should receive the COVID-19 vaccine regardless of prior infection.

- Natural Immunity
 - When you've had the actual disease and produced antibodies for protection
 - Unknown length of protection at this time
 - Ongoing studies
- Passive Immunity
 - Immunity produced by your body after vaccination
 - Too early to know
 - Generally, less robust

Every eligible person should receive a COVID-19 Vaccine when available regardless of previous infection.

If you have questions, please consult your primary care provider

—

“I cannot get
COVID-19 after
receiving the
first vaccine
injection.”



Myth: You can still get COVID-19 after receiving the first dose of vaccine.

- It typically takes a few weeks for the body to build immunity after vaccination. That means it's possible a person could be infected with the virus that causes COVID-19 just before or just after vaccination and get sick. This is because the vaccine has not had enough time to provide protection.
- Full benefit of protection will not occur until a few weeks after the second dose.



“I have a chronic disease that makes me immunosuppressed, therefore I should not receive the vaccine.”


Myth: Even immunosuppressed patients should receive the COVID-19 vaccine.

According to the EAU Package Insert:

Contraindications:

Do not administer Pfizer-BioNTech COVID-19 Vaccine to individuals with known history of a SEVERE allergic reaction (e.g., anaphylaxis) to any component of the Pfizer-BioNTech COVID-19 Vaccine.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Pfizer-BioNTech COVID-19 Vaccine.



“If I get the vaccine, I won’t have to continue to wear the PPE.”



Myth: It is recommended that everyone continue to practice CDC PPE recommendations until further notice...

- Even after receiving the vaccine series, you will still be required to continue practicing infection control precautions which will include good hand hygiene and wearing appropriate PPE which includes a mask that covers your mouth and nose.
- Once we reach a certain level of our population that is vaccinated, we expect that the CDC will provide guidance on when we can relax our PPE use as a nation.



What you can do now to be prepared.

RICHARDS & RICHARDS
DESTRUCTION DIVISION

What you can do now to be prepared.

Discussions between:

**Partner,
Dept. of Health
and Wellpath**

- Prioritization and timing of vaccinations for custody, health care staff, patients, other
- Vaccination Logistics - Supplies, location, movement for clinic
- State deployment and local DOH deployment plan
- Vaccination Planning Tool
 - Storage
 - Training and Fact Sheets
 - Staggering
 - Supplies / Location
 - Reactions / Adverse response
 - Survey for interest
 - Record keeping

The image features three glass vials with silver caps and a syringe. The vials are labeled 'COVID-19 VACCINE' in red and black text. The syringe is positioned horizontally in the foreground, with its needle pointing to the right. The background is a dark, reflective surface.

Don't Hesitate.
Vaccinate!

(that includes Flu, too!)

Thank you